LAUSR

Objective: Determination of the severity of comorbid pathology in patients with acute myocardial infarction. Design and method: The retrospective study included 634 medical records of a patient with myocardial infarction. Statistical processing was carried out using the SPSS 13 software. To compare qualitative variables, the Pearson 2 test was used for paired values. Differences in the data were considered statistically significant at p < 0.05. To compare the groups, we used the ANOVA test. One-way Pearson correlation analysis was carried out. Results: The comorbidity of AMI patients was assessed using the Charlson comorbidity index. The patients were divided into 3 groups: Group I (low comorbidity, CI < 3 points) accounted for 4.4% of the patient; Group II (average comorbidity, CI 3–5 points) - 48.3% of the patient; Group III (high comorbidity, CI more 5 points) - 47.3% of the patient. Charlson’s comorbidity index was 5.5 ± 1.9 points. The total number of nosologies in AMI patients also increased with age (r = 0.741, p = 0.001). Low comorbidity was found in 92.9% of men and 7.1% of women. Average comorbidity: 75.2% and 24.8%, respectively. Patients with a high Charlson comorbidity index were defined in the same way in 49.7 % men and 50.3% women, p = 0.0001. Patients with high comorbidity were more likely to have anemia than patients with low comorbidity. 28.3% and 10.7% cases, pIII – I = 0.0001. It was also revealed that the higher the comorbidity index was, the higher the troponin level was (p = 0.024). Conclusions: In the studied patients with AMI, a high degree of severity of comorbidity was determined. The total number of nosologies in AMI patients increased with age. High comorbidity, which increased with age, was defined in the same way in both men and women. Patients with a high severity of comorbidity was level of troponin in the blood was higher, possibly related to age, which is associated with a worse hospital prognosis. When calculating the comorbidity index, Charlson showed a low 10-year survival rate of our patients (21%).